Drug news
FDA accepts filing of Zohydro ER for Chronic Pain treatment
The FDA has accepted for review the new drug application (NDA) for the oral, extended-release hydrocodone therapy ZohydroER from Zogenix Inc., as a treatment for moderate to severe Chronic Pain.The FDA set 1 March 2013 as the Prescription Drug User Fee Act action date � granting a 10-month standard review.